Christopher Poon

Christopher Poon

Auto-generated profile, based on publicly available information

Christopher Poon

Department of Biomedical Engineering, University of Southern California , Los Angeles, CA 90089 , USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Biomaterials
Verified
Journal Article
Closed access
DCDeborah D. Chin
Deborah D. Chin
CPChristopher Poon
Christopher Poon
JWJonathan Wang
Jonathan Wang
JJJohan Joo
Johan Joo
VOVictor Ong
Victor Ong
ECEun Ji Chung
Eun Ji Chung

3 April 2020 in Nano Express
Verified
Journal Article
Open access
PDF file
CPChristopher Poon
Christopher Poon
APAmish A Patel
Amish A Patel
Infectious diseases remain a leading cause of concern worldwide. Conventional vaccine methods to elicit immune responses have limitations in effectively controlling new and re-merging pathogens. Nanoparticle-based vaccines show promise in overcoming these limitations due to their versatility and tunability to protect antigen from premature degradations, facilitate their intracellular uptakes and elicit prolonged immunity against infectious diseases. Nanoparticle can be categorized as purely organic or inorganic based on the components that construct the structure. Most organic materials are biocompatible, biodegradable, and nontoxic, while most inorganic materials have a smaller particle size, improved stability, controlled tunability, enhanced permeability, high antigen loadings, and a triggered release profile. This review will focus on the different type of organic and inorganic nanoparticles used as vaccine against infectious diseases.

15 November 2018 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
CPChristopher Poon
Christopher Poon
Juan GalloJuan Gallo
Juan Gallo
JJJohan Joo
Johan Joo
TCTimothy Chang
Timothy Chang
MBManuel Bañobre-López
Manuel Bañobre-López
ECEun Ji Chung
Eun Ji Chung
Atherosclerosis, a major source of cardiovascular disease, is asymptomatic for decades until the activation of thrombosis and the rupture of enlarged plaques, resulting in acute coronary syndromes and sudden cardiac arrest. Magnetic resonance imaging (MRI) is a noninvasive nuclear imaging technique to assess the degree of atherosclerotic plaque with high spatial resolution and excellent soft tissue contrast. However, MRI lacks sensitivity for preventive medicine, which limits the ability to observe the onset of vulnerable plaques. In this study, we engineered hybrid metal oxide-peptide amphiphile micelles (HMO-Ms) that combine an inorganic, magnetic iron oxide or manganese oxide inner core with organic, fibrin-targeting peptide amphiphiles, consisting of the sequence CREKA, for potential MRI imaging of thrombosis on atherosclerotic plaques. Hybrid metal oxide-peptide amphiphile micelles, consisting of an iron oxide (Fe-Ms) or manganese oxide (Mn-Ms) core with CREKA peptides, were self-assembled into 20–30 nm spherical nanoparticles, as confirmed by dynamic light scattering and transmission electron microscopy. These hybrid nanoparticles were found to be biocompatible with human aortic endothelial cells in vitro, and HMO-Ms bound to human clots three to five times more efficiently than its non-targeted counterparts. Relaxivity studies showed ultra-high r2 value of 457 mM−1 s−1 and r1 value of 0.48 mM−1 s−1 for Fe-Ms and Mn-Ms, respectively. In vitro, MR imaging studies demonstrated the targeting capability of CREKA-functionalized hybrid nanoparticles with twofold enhancement of MR signals. This novel hybrid class of MR agents has potential as a non-invasive imaging method that specifically detects thrombosis during the pathogenesis of atherosclerosis.

3 February 2020 in Advanced Therapeutics
Verified
Journal Article
Open access
PDF file
DCDeborah D. Chin
Deborah D. Chin
CPChristopher Poon
Christopher Poon
NTNoah Trac
Noah Trac
JWJonathan Wang
Jonathan Wang
JCJackson Cook
Jackson Cook
ECEun Ji Chung
Eun Ji Chung
Atherosclerosis is an inflammatory disease characterized by plaques that can cause sudden myocardial infarction upon rupture. Such rupture‐prone plaques have thin fibrous caps due to collagenase degradation, and a noninvasive diagnostic tool and targeted therapy that can identify and treat vulnerable plaques and may inhibit the onset of acute cardiac events. Toward this goal, monocyte‐binding, collagenase‐inhibiting, and gadolinium‐modified peptide amphiphile micelles (MCG PAMs) are developed. Monocyte chemoattractant protein‐1 (MCP‐1) binds to C‐C chemokine receptor‐2 expressed on pathological cell types present within plaques. Through the peptide binding motif of MCP‐1, MCG PAMs bind to monocytes and vascular smooth muscle cells in vitro. Moreover, using magnetic resonance imaging, MCG PAMs show enhanced targeting and successful detection of plaques in diseased mice in vivo and act as contrast agents for molecular imaging. Through the collagenase‐cleaving peptide sequence of collagen [VPMS‐MRGG], MCG PAMs can compete for collagenases that degrade the fibrous cap of plaques, providing therapy. MCG PAM‐treated mice show increased fibrous cap thickness by 61% and 113% histologically compared to nontargeting micelle‐ or PBS‐treated mice (p = 0.0075 and 0.001, respectively). Overall, this novel multimodal nanoparticle offers new theranostic opportunities for noninvasive diagnosis and treatment of atherosclerotic plaques.

27 October 2018 in Molecules
Verified
Journal Article
Open access
PDF file
JJJohan Joo
Johan Joo
CPChristopher Poon
Christopher Poon
SYSang Pil Yoo
Sang Pil Yoo
ECEun Ji Chung
Eun Ji Chung
Peptide amphiphile micelles (PAMs) are a nanoparticle platform that have gained popularity for their targeting versatility in a wide range of disease models. An important aspect of micelle design is considering the type of hydrophobic moiety used to synthesize the PAM, which can act as a contributing factor regarding their morphology and targeting capabilities. To delineate and compare the characteristics of spherical and cylindrical micelles, we incorporated the monocyte-targeting chemokine, monocyte chemoattractant protein-1 (MCP-1), into our micelles (MCP-1 PAMs). We report that both shapes of nanoparticles were biocompatible with monocytes and enhanced the secondary structure of the MCP-1 peptide, thereby improving the ability of the micelles to mimic the native MCP-1 protein structure. As a result, both shapes of MCP-1 PAMs effectively targeted monocytes in an in vitro binding assay with murine monocytes. Interestingly, cylindrical PAMs showed a greater ability to attract monocytes compared to spherical PAMs in a chemotaxis assay. However, the surface area, the multivalent display of peptides, and the zeta potential of PAMs may also influence their biomimetic properties. Herein, we introduce variations in the methods of PAM synthesis and discuss the differences in PAM characteristics that can impact the recruitment of monocytes, a process associated with disease and cancer progression.

30 April 2024 in PNAS Nexus
Verified
Journal Article
Open access
PDF file
YHYi Huang
Yi Huang
JWJonathan Wang
Jonathan Wang
VMValeria Mancino
Valeria Mancino
JPJessica Pham
Jessica Pham
COColette O’gRady
Colette O’gRady
ECEun Ji Chung
Eun Ji Chung
Chronic and genetic kidney diseases such as autosomal dominant polycystic kidney disease (ADPKD) have few therapeutic options, and clinical trials testing small molecule drugs have been unfavorable due to low kidney bioavailability and adverse side effects. Although nanoparticles can be designed to deliver drugs directly to the diseased site, there are no kidney-targeted nanomedicines clinically available, and most FDA-approved nanoparticles are administered intravenously which is not ideal for chronic diseases. To meet these challenges of chronic diseases, we developed a biomaterials-based strategy using chitosan particles (CP) for oral delivery of therapeutic, kidney-targeting peptide amphiphile micelles (KMs). We hypothesized that encapsuling KMs into CP would enhance the bioavailability of KMs upon oral administration given the high stability of chitosan in acidic conditions and mucoadhesive properties enabling absorption within the intestines. To test this, we evaluated the mechanism of KM access to the kidneys via intravital imaging and investigated the KM biodistribution in a porcine model. Next, we loaded KMs carrying the ADPKD drug metformin into CP (KM-CP-met) and measured in vitro therapeutic effect. Upon oral administration in vivo, KM-CP-met showed significantly greater bioavailability and accumulation in the kidneys as compared to KM only or free drug. As such, KM-CP-met treatment in ADPKD mice (Pkd1fl/fl;Pax8-rtTA;Tet-O-Cre which develops the disease over 120 days and mimics the slow development of ADPKD) showed enhanced therapeutic efficacy without affecting safety despite repeated treatment. Herein, we demonstrate the potential of KM-CP as a nanomedicine strategy for oral delivery for the long-term treatment of chronic kidney diseases.